ERBB2 and neoplasm: In the present study, the novel anti-HER2 macrophage (Anti-HER2 Macrophage, HM)integrates the active targeting capability towards HER2-positive tumors with the therapeutic efficacy of monoclonal antibodies, marking a pioneering approach to eliminate tumor cells.